Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldesleukin - Novartis

Drug Profile

Aldesleukin - Novartis

Alternative Names: Chiron IL-2; IL-2; IL-2 - Chiron; interleukin-2 - Chiron; Macrolin™; Proleukin; Recombinant IL-2; Recombinant-human-interleukin-2 - Chiron; T cell growth factor

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron
  • Developer Hyup Jin Corporation; Ligand Pharmaceuticals; Novartis
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders; Malignant melanoma; Renal cell carcinoma; Acute myeloid leukaemia; Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma; Renal cell carcinoma
  • Discontinued HIV-1 infections; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Aug 2017 Prometheus Laboratories terminates a phase II trial due to slow accrual for Malignant melanoma (Metastatic disease, Late-stage disease, Second-line or greater therapy) in USA (IV) (NCT02796352)
  • 01 Sep 2016 Prometheus Laboratories initiates a phase II trial for Malignant melanoma (Metastatic disease; Late-stage disease, Second-line or greater therapy) in USA (NCT02796352)
  • 15 Jun 2016 Prometheus Laboratories plans a phase II trial for Malignant melanoma (Metastatic disease; Late-stage disease, Second-line or greater therapy) in USA (NCT02796352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top